FDA granted Fast Track designation to HM43239, an oral, myeloid kinome inhibitor, for the treatment of patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with FLT3 mutation.
The European Commission approved Kymriah (tisagenlecleucel), a CAR-T cell therapy, for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
The European Commission has approved the use of Cabometyx (cabozantinib) as a monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma, refractory or not eligible to radioactive iodine who have progressed during or after prior systemic therapy.
Myriad Genetics Inc. expanded its partnership with Intermountain Precision Genomics to add a new liquid biopsy therapy selection test to its oncology portfolio.
Aadi Bioscience Inc. has received a product-specific, permanent J-code for Fyarro (sirolimus protein-bound particles for injectable suspension) (albumin-bound) for intravenous use for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).
The National Cancer Institute approved the following clinical research studies last month.
FDA has announced proposed product standards that would prohibit menthol as a characterizing flavor in cigarettes and prohibit all characterizing flavors other than tobacco in cigars.
MD Anderson, Community Health Network announce partnership to create fully integrated cancer program
The University of Texas MD Anderson Cancer Center and Indianapolis-based Community Health Network announced a partnership agreement to create Community Health Network MD Anderson Cancer Center.
Shelley Johns was named the Walther Scholar in Psycho-Oncology at Indiana University School of Medicine.
UC Davis Comprehensive Cancer Center is launching the Center for Advancing Cancer Health Equity, which will conduct community-engaged research and interventions.
